Amgen Kineret
Executive Summary
FDA's Arthritis Advisory Committee will discuss Amgen's anakinra filing for reduction in signs and symptoms of active rheumatoid arthritis on Aug. 16, beginning at 8 a.m. FDA has cleared the trade name Kineret for anakinra, Amgen said